Federal lawmakers have renewed efforts to pass legislation ensuring Medicare coverage of multi-cancer early detection (MCED) tests.
Subscribe today for access to
Articles and Reports
Ruling could spell good news for labs and other healthcare providers targeted by whistleblowers in False Claims Act qui tam lawsuits.
Congress is renewing its previous efforts to make Medicare reimbursement of pharmacy testing permanent—here’s what that could mean for labs.
The VALID Act for FDA regulation of laboratory developed tests is working its way through the final stages of the legislative process, but not everyone is loving it.
After years of resistance, the lab industry’s hopes and prayers for relief from the flawed pricing scheme may soon be answered.
The most recent congressional effort to pass LDT legislation may prove to be the one that finally comes to fruition.
A briefing on how labs should prepare for the inevitable end of the PHE after more than two years of unprecedented relief.
The relief package agreed to on April 4 appears to have become a collateral victim of a politically incendiary issue regarding immigration.
Legislation would require Medicare to cover genomic cancer testing and follow-up screening for those with a family history of cancer.